香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 海外監管公告 本 公 告 乃 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市規則第13.10B條而發表。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 的《康 希 諾 生 物 股 份 公 司2025年年度報 告摘要》《康希諾生物股份公司2025年年度報告》《康希諾生物股份公司第三屆董 事會第十次會議決議公告》《康希諾生物股份公司關於2025年度利潤分配方案的 公告》《康希諾生物股份公司關於續聘會計師事務所的公告》《康希諾生物股份公 司關於提請股東會授權董事會以簡易程序向特定對象發行股票的公告》《康希諾 生物股份公司關於2026年度對外擔保預計的公告》《康希諾生物股份公司2025年 ...

Macro Strategy - In August, the LPR remained unchanged, with the 1-year loan market quoted rate at 3.00% and the 5-year rate at 3.50%, marking the third consecutive month of stability after a reduction in May [3][4] - Public fiscal expenditure in July showed a year-on-year growth of 3.04%, ending a decline seen in May and June, with a cumulative growth of 3.40% for the first seven months [4] Stock Market Overview - From August 18 to August 22, A-share indices experienced significant increases, with the Shanghai Composite Index rising by 3.49% and the ChiNext Index by 5.85%, among others [5][6] - All 31 first-level industries in the A-share market saw gains, with the communication and electronics sectors leading with weekly increases of 10.84% and 8.95% respectively [6][7] - The overall market is expected to maintain a "slow bull" trend, supported by new policies and investment strategies [7][8] North Exchange Market - As of August 22, 2025, the North Exchange had 273 listed stocks, with an average total market capitalization of 919.56 billion yuan, reflecting a 7.75% increase from the previous week [9][10] - Newly listed companies such as Hongyuan Co. and Nengzhiguang saw substantial weekly gains of 281.90% and 344.38% respectively [9][10] - The liquidity in the North Exchange improved significantly, with average trading volume increasing by 55.06% and average trading value by 62.92% [10] Pharmaceutical Industry - Kangxino's half-year report for 2025 showed a revenue of 382 million yuan, a 26% year-on-year increase, with a narrowed net loss of 13.49 million yuan [14][15] - The growth was primarily driven by the sales of its meningitis product, especially the Mankaixin, which achieved a revenue of 364 million yuan, up 38.43% year-on-year [15][16] - The company is expanding its market presence with plans for new product launches and international collaborations, particularly for its pneumonia vaccine [16][17] Chemical Industry - The "anti-involution" policy is expected to lead to the elimination of outdated production capacity in the soda ash sector, potentially improving industry conditions [21][22] - The soda ash market has been under pressure due to oversupply, but the removal of older production facilities could help stabilize prices [21][22]